The first 60 days: Buccal mucosa and gingivobuccal cancer (oral cancer in India)
Cancer of the cheek lining and gums is India's commonest cancer in men, caused by chewing tobacco and areca nut. Surgery with reconstruction is the mainstay, and trials from Tata Memorial in Mumbai have shown that removing the neck nodes up front, cheap oral chemotherapy, tiny doses of immunotherapy and visual screening by health workers all save lives at low cost. Below, week by week, is what OnCo's record of Buccal mucosa and gingivobuccal cancer (oral cancer in India) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Resectable disease, Borderline resectable (masticator space involvement).
- Medical oncologistNamed in the standard of care for: Borderline resectable (masticator space involvement), After surgery, Palliative and recurrent disease.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Resectable disease, Borderline resectable (masticator space involvement), After surgery.
- Palliative and supportive care teamNamed in the standard of care for: Prevention.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Visual oral examination by trained health workers for tobacco and alcohol users (Kerala trial); treatment of leukoplakia and management of oral submucous fibrosis.
Smokeless tobacco and areca nut cessation, gutka bans, and oral screening in high-risk people.
- 3.Resectable diseaseNCCN category Category 1 (elective neck dissection), NCCN Guidelines: Head and Neck Cancers
Wide excision with marginal or segmental mandibulectomy as needed, elective or therapeutic neck dissection (Tata Memorial trial), and free-flap reconstruction.
Induction docetaxel-cisplatin-fluorouracil to shrink technically unresectable tumours, then surgery in responders (Tata Memorial practice); chemoradiation otherwise.
Postoperative radiotherapy for advanced stage, perineural invasion or nodes; cisplatin chemoradiation for extranodal extension or positive margins.
Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS); pembrolizumab where available.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Depth of invasion and bone invasion, Masticator space involvement, Extranodal extension and margin status, Oral submucous fibrosis and leukoplakia, TP53 mutation), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Buccal mucosa squamous cell carcinoma, Gingivobuccal sulcus and lower alveoluscancer, Retromolar trigone cancer.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Screening in high-risk populations
- For my situation (screening in high-risk populations), which of the standard options do you recommend and why?Guideline options include: Visual oral examination by trained health workers for tobacco and alcohol users (Kerala trial); treatment of leukoplakia and management of oral submucous fibrosis.
- How do the results of Kerala oral cancer visual screening trial (Trivandrum) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Resectable disease
- For my situation (resectable disease), which of the standard options do you recommend and why?Guideline options include: Wide excision with marginal or segmental mandibulectomy as needed, elective or therapeutic neck dissection (Tata Memorial trial), and free-flap reconstruction.
- How do the results of Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Borderline resectable (masticator space involvement)
- For my situation (borderline resectable (masticator space involvement)), which of the standard options do you recommend and why?Guideline options include: Induction docetaxel-cisplatin-fluorouracil to shrink technically unresectable tumours, then surgery in responders (Tata Memorial practice); chemoradiation otherwise.
- Am I a candidate for Docetaxel, Cisplatin, Fluorouracil (5-FU), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
After surgery
- For my situation (after surgery), which of the standard options do you recommend and why?Guideline options include: Postoperative radiotherapy for advanced stage, perineural invasion or nodes; cisplatin chemoradiation for extranodal extension or positive margins.
- Am I a candidate for Cisplatin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Palliative and recurrent disease
- For my situation (palliative and recurrent disease), which of the standard options do you recommend and why?Guideline options include: Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS); pembrolizumab where available.
- Am I a candidate for Methotrexate, Nivolumab, Pembrolizumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) and Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Prevention
- For my situation (prevention), which of the standard options do you recommend and why?Guideline options include: Smokeless tobacco and areca nut cessation, gutka bans, and oral screening in high-risk people.
Any stage
- Are there clinical trials I could join, for example of Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), METRO PLUS (Tata Memorial Centre, Varanasi), Oral cancer visual screening, NIVOPOSTOP (GORTEC 2018-01)?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Late presentation and rising incidence as areca nut and gutka use spread”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Access to pembrolizumab, cetuximab and radiotherapy machines outside big cities”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Buccal mucosa and gingivobuccal cancer (oral cancer in India): the full pageCancer of the cheek lining and gums is India's commonest cancer in men, caused by chewing tobacco and areca nut. Surgery with reconstruction is the mainstay, and trials from Tata Memorial in Mumbai have shown that removing the neck nodes up front, cheap oral chemotherapy, tiny doses of immunotherapy and visual screening by health workers all save lives at low cost.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Extranodal extension (ENE): Extranodal extension means cancer in a lymph node has burst through the node's capsule into the surrounding fat; in head and neck cancer it is the single finding after surgery that most often turns radiotherapy into chemoradiotherapy, and in HPV-negative disease it moves the stage up.
- Depth of invasion (DOI): Depth of invasion is how far down a cancer has grown from the surface it started on, measured in millimetres on the pathology slide; in mouth cancer it now sets the T stage and a depth over 4 mm means the neck nodes are treated even when they look clean, and in early stomach cancer it decides whether an endoscopic removal was enough.
- Chemoradiation (chemoradiotherapy, CRT): Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation.
Every term links to the glossary.